Alan Morgan was appointed Group President Clinical Research Services in August 2010 prior to this he held the position of Group President Early Clinical Research and Laboratories, responsible for oversight of the Central Laboratory Division and the Development Services Division.  

He joined the company in August 2006 where he initially held the position of Vice President of Process Development for ICON plc, later the President of ICON Clinical Europe, and until January of 2010,  Chief Operating Officer of the global Clinical Research Division.

Before joining ICON Alan was US based as Global General Manager and Vice President of the Phase II/IV business of MDS Pharma Services, responsible for Project Management, Clinical Operations, Data Management and Biostatistics, Regulatory Affairs, and all of the commercial operations of the business.  He joined MDS in 2002 as General Manager  and Vice President  of their European, Latin American and Asian, clinical development operations. 

Alan started his career in Clinical Research Organisations with Covance, where he held a number of leadership positions  from 1998  including General Manager of their Phase II/IV business in Europe, Asia, and Latin America.

His initial career was in pharma, including seven years with Glaxo Wellcome and two years with ICI Pharmaceuticals in various business  and  financial roles.

He is a graduate of the City University Business School in London,  and a Fellow of the Chartered Association of Certified Accountants.
 

Linda joined ICON as the Chief Operating Officer, ICON Clinical Research in August, 2010.  She has 30 years of pharmaceutical industry experience and is a globally recognized expert in the organization, resourcing and conducting of clinical trial programs.  Linda also holds a number of Advisory Board Member positions within the pharmaceutical industry.

Just prior to joining ICON, Linda served as Vice President, Global Clinical Operations at Glaxo Smith Kline (GSK) where she was responsible for Clinical Operations, Data Management, Training, Grants and Contracts, Alliance partnerships, SOP’s and Policies.  She joined GSK in 2001 where she developed the global operations clinical trial organization.

Linda started her career at Johnson and Johnson Pharmaceutical where she held a number of leadership positions from 1991 - 2001.

Linda is a registered pharmacist and a graduate of St. John’s University.
 

Dana has been with the company since March 1997, she initially joined as a Project Manager. Dana has held positions of increasing responsibility at ICON inclusive of Senior Vice President, US Clinical Operations for 5 years. Dana’s clinical research experience began as a CRA progressing to Project Manager during five years with ClinTrials Research. She began her career in health care as a neonatal intensive care nurse at Vanderbilt University prior to entering clinical research industry.

Malcolm Burgess joined ICON in December 2002 as Senior Vice President, Biometrics, and Data Management. In April 2006 Malcolm was appointed as Chief Operating Officer, US Operations. In addition he still maintains global leadership of the Biometrics and IVRS groups within ICON Clinical Research.
Prior to joining ICON Clinical Research, Dr Burgess held the position of Executive Director, Global Electronic Data Capture Logistics for Novartis. He has nearly 30 years experience within the Pharmaceutical sector having held various Research and Development positions within Novartis, Hoechst Marion Roussel and SmithKline Beecham.

Dr Burgess holds a BSc in Chemistry from University College, London and a Doctorate in Biochemistry and Physiology from Bath University, UK.

Suzanne has been with ICON since 2001 and has held the following positions: Sr. Vice President, US Medical and Regulatory Affairs, Sr. Vice President, Medical Affairs and Late Phase Services and Head, Global Medical Affairs and Drug Safety. She was promoted to Chief Medical Officer in June, 2008.

Suzanne has more than 20 years of experience in pharmaceutical research and development. Prior to joining ICON, she held various management and senior management positions in Medical Affairs and Clinical Research and Development at Rhone-Poulenc Rorer, Luitpold Pharmaceuticals and Omnicare Clinical Research. Her background includes eight years in academic medicine at Boston University, the University of Miami and as the Director of Clinical Research at the University of Kansas School of Medicine She is a former member of the University of Miami’s AIDS Clinical Trials Group, sponsored by the National Institutes of Allergy and Infectious Diseases.

Suzanne received her medical degree from Boston University School of Medicine, is board certified in Internal Medicine and is a Fellow of the American College of Physicians. She has held a number of academic faculty appointments and has published articles and abstracts on drug safety and in therapeutic areas including HIV disease, chronic renal failure and oncology. She currently lectures in Pharmaceutical Product Development and Drug Safety & Risk Management at West Chester University.

Jonathan Goldman MD FACC FRCP
Executive Vice President Strategic Programs

Dr. Goldman joined ICR in April 2010 to lead the Strategic Programs group, with responsibility for strategic relationships and alliance management.   Prior to this, he served as Chief Medical Officer and Senior Vice President of Medical Affairs at ICON Medical Imaging, where he initiated numerous technological and cross-divisional innovations for endpoint adjudication, as well as enhanced scientific relationships. From 2001 to 2007 he was the Chief Medical Officer and Vice President of Medical Affairs at Point Biomedical, a biopharmaceutical company, with responsibility for medical affairs, clinical operations, data management and biostatistics.

He graduated with a distinction in his medical qualification at St. Bartholomew's Hospital Medical College in London in 1989.  He then completed a cardiology fellowship at St. George’s Hospital, London, one of the UK’s leading cardiac institutions in 1999, and a cardiac echocardiography fellowship at the University of California, San Francisco in 2000.

He is certified in internal medicine, cardiology, and several cardiac subspecialties. He has authored over 100 scientific publications, and is a Fellow of 7 prominent medical societies including the American College of Cardiology and the Royal College of Physicians of the UK.  He currently maintains a Faculty appointment as an Assistant Clinical Professor of Medicine at the University of California, San Francisco, and serves as attending Cardiologist at the San Francisco Veterans’ Administration Medical Center.
 

Dr. Peter Sowood, is the Chief Scientific Officer for ICON Clinical Research since March 2007 prior to this he served the company as President of ICON Clinical Research Europe since November 2003. Before joining the Company, Dr. Sowood held various positions at Covance Clinical and Periapproval Services, Ltd., including the position of Vice-president Clinical Research.

Dr. Sowood was educated at the University of Cambridge in Medical Sciences and followed on to Oxford University where he took Medical Degrees before joining the RAF as a Medical Officer. Dr. Sowood obtained his PhD in 1988 and MBA in 1993

Kris Gustafson has been with ICON since 2000 in multiple roles and positions. In January 2007 he was promoted into his current role as Global Head of the Interactive Technologies business unit and the Life Sciences business unit. Prior to ICON, Kris was President and co-founder of Electronic Trial Management Technologies, a technology company specializing in IVR and IWR solutions for clinical trials, which was acquired by ICON in 2000. From 1995-1999 he served as Senior Director of Information Management at Applied Logic Associates. From 1990-1995 he worked as a Mechanical Engineer in the Nuclear sector.

Kris received his Bachelor of Science degree Mechanical Engineering from Washington State University in 1990.

Charles has over 20 years of experience in the pharmaceutical, biotechnology, and CRO industries. Currently, he is the Senior Vice President, Global Biostatistics and Programming at ICON Clinical Research. Charles started his career as a statistician supporting clinical research at Syntex (subsequently acquired by Roche), moved to Liposome Technology (renamed SEQUUS and subsequently acquired by Johnson & Johnson), before founding Pacific Research Associates (acquired by ICON in January 2000) with three other partners in 1995.

Dr. Du Mond has a PhD in Statistics from the University of Iowa.